<DOC>
	<DOCNO>NCT02558153</DOCNO>
	<brief_summary>A multicenter randomize clinical trial paclitaxel drug-eluting balloon ( DEB ) versus standard percutaneous transluminal angioplasty ( PTA ) reduce restenosis 150 patient haemodialysis access stenosis .</brief_summary>
	<brief_title>RCT Paclitaxel DEB Compared Standard PTA Dialysis Fistula</brief_title>
	<detailed_description>Prospective multicenter randomize ( 1:1 ) Investigator Sponsored Trial , 150 consecutive patient candidate percutaneous intervention haemodialysis access randomly assign one two study arm : 1 . Treatment Arm : paclitaxel drug-eluting balloon ( DEB ) dilatation use APERTO-balloon 2 . Control Arm : standard percutaneous transluminal angioplasty ( PTA ) . The aim evaluate safety efficacy paclitaxel drug-eluting balloon ( DEB ) reduction restenosis haemodialysis shunt compare standard percutaneous transluminal angioplasty ( PTA ) .</detailed_description>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>All criterion 110 must apply inclusion . 1 . Age &gt; 18 year &lt; 90 year 2 . Patient legally authorize representative provide write informed consent 3 . Patient willing likely comply follow schedule 4 . Patients previously well function hemodialysis access arm presenting follow clinical abnormality define NKFDOQIprotocol criterion ( National Kidney Foundation 2000 ) : Abnormal physical examination finding ( change bruits , thrill , pulse , etc Abnormal urea recirculation measurement Elevated venous pressure dialysis Decreased access flow Previous thrombosis access line Development collateral vein Limb swell Low arterial pressure dialysis Unexplained decrease dialysis dose 5 . Target Lesion hemodynamically relevant consist MLD â‰¤ 3 mm . For enrolment criterium judge local investigator . For final analysis criterium base result central reading angiogram . 6 . Target Lesion ( ) denovo ( nonstent ) restenosis 7 . Target lesion ( ) dialysis fistula locate anastomosis outflow venous trajectory level ( exclude ) subclavian vein 8 . Target lesion ( ) dialysis graft locate arterial venous anastomosis , inside graft , outflow venous trajectory level ( exclude ) subclavian vein 9 . Multiple Target Lesions allow per patient treat number APERTO DEB aggregate max length 160 mm 10 . NON Target Lesions ( i.e . subclavian vein ) must successfully treat standard PTA prior Target Lesion . None criteria 112 must apply inclusion . 1 . Patients unable give inform consent 2 . Patients enrol another study investigational drug device 3 . Patients previously enrol APERTO trial . 4 . Female patient child bear potential without negative pregnancy test time intervention 5 . Major surgical procedure within 30 day prior study plan within 30 day entry study 6 . Patients previously treat DEB hemodialysis access . 7 . Patients trombosed hemodialysis access . 8 . Immature hemodialysis access ( unusable due insufficient shunt flow volume ) 9 . Lesion treat within 30 day prior screen 10 . Failure successfully treat nontarget lesion prior Target Lesion 11 . In stent restenosis 12 . Patients know allergy , hypersensitivity intolerance ASA , clopidogrel ticlopidine , paclitaxel , contrast medium . 13 . Graft infection 14 . Life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>drug elute balloon</keyword>
	<keyword>percutaneous balloon angioplasty</keyword>
</DOC>